Cloud-Native Drug Discovery
From the “AI Pilot Graveyard” to Enterprise- Grade Impact
Accelerating Cross-Sector Integration in Pharma and Nutraceuticals
Early-Phase Oncology Trials Shaping the Future of Cancer Research
Tailored Artificial Intelligence (AI)
EDITORIAL SECTION
-
STRATEGY
Smarter Pharma
Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solution
-
CLINICAL TRIALS
Why Clinical Trials Need Digital Endpoints
According Citeline the average success rate for bringing a Phase candidate to market has dropped to an alltime low of just
-
MANUFACTURING
Ensuring Quality and Compliance in Biopharma
Ensuring quality and regulatory compliance in the biopharmaceutical industry is critical to safeguarding product safety and efficacy
-
Information Technology
The Cost of Bad Data
Modern pharmaceutical research generates an unprecedented volume of information Data from genomic sequencing
-
Biopharma
Reimagining Global Biomanufacturing Capacity with Continuous and Modular Systems
Biotechnology is fueling the ongoing expansion of the global market for a broad array of goods
-
EXPERT Talk
Compliance to Competitive Advantage in Pharma Supply
Compliance gets you through an audit Resilience gets medicines to patients on the day something unexpected happens The DSCSAs enhanced requirements took effect November but real interoperability required three more rounds of accommodation phased implementation with the smalldispenser
Advisory Board
.webp)
KNOWLEDGE BANK
-
Articles
The Future of Oncology Clinical Trials: Adaptive, Biomarker-Led, and AI-Enabled
Oncology now absorbs close to a third of the industrys active development pipeline and a comparable share of its research budget It also carries the worst odds in medicine A molecule entering firstinhuman cancer studies has historically had a midsingledigit probability of reaching approval against roughly double that across other therapy areas For a European chief executive allocating capital acro...
Medical Devices and Pharma: A Symbiotic Relationship for Improved Healthcare
The healthcare industry is continually evolving driven by technological advancements and innovative approaches to patient care Among the most significant developments is the symbiotic relationship between medical devices
How AI Is Addressing Drug Development Challenges in Rare Diseases?
Healthcare struggles with persistent obstacles to treat and understand rare diseases which societies call orphan diseases While affecting a minority portion of individuals these rare diseases make therapy discovery difficult because of scarce research data and expensive evaluation costs alongside multifaceted disease pathways The rising use of artificial intelligence AI drives a transformative cha...
What Are the Benefits of Implementing a Modern MES in Pharma?
The pharmaceutical sector is rapidly changing in a bid to match the increasing pressure of regulation attain perfection in product quality and hasten the timetomarket A Pharma MES or Manufacturing Execution System is one of the most strategic investments that are strategically placed in this environment in terms of operational excellence
Reshaping Biologics Production Integrating Human Intelligence, AI, and Digital Twins for a Resilient Biologics Future
Biological medicines are not manufactured They are cultivated Every monoclonal antibody plasmaderived immunoglobulin and biosimilar molecule begins its journey inside a living cell That origin creates a category of operational challenge with no equivalent in smallmolecule production the product is the process Variations in temperature pH dissolved oxygen or nutrient concentration do not merely aff...
The Permanent Prescription: Why Gene Therapy Is Rewriting the Rules of Drug Safety
Gene therapy has moved from laboratory promise to clinical reality offering something medicine has rarely been able to promise before a single treatment capable of curing a disease rather than merely managing it Yet this same quality of permanence is quietly undermining the safety systems the pharmaceutical industry has relied on for decades Adverse events can emerge a decade
-
Techno Trends
Alume Biosciences Secures FDA Breakthrough Therapy Designation for Bevonescein
Alume Biosciences has received Breakthrough Therapy Designation BTD from the US Food and Drug Administration FDA for bevonescein an investigational fluorescent drug being developed to support realtime nerve visualisation during head and neck surgery in adults Bevonescein is an intravenous fluorescent peptidedye conjugate that binds to nerve tissue
-
Projects
SK pharmteco Plans More Than US$200 Million Investment in Small Molecule and Peptide Manufacturing
SK pharmteco is planning a fiveyear investment of more than US million to expand and modernise its pharmaceutical development and manufacturing operations in the United States The programme will strengthen capabilities for small molecules and peptides while supporting a more
-
Research Insights
A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG
PIGACDG is a congenital disorder of glycosylation caused by pathogenic partial lossoffunction variants in the PIGA gene PIGA encodes an enzyme responsible for the catalytic transfer of Nacetylglucosamine
-
whitepaper
Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact
For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys
TOP ARTICLES
-
1
Medical Devices and Pharma: A Symbiotic Relationship for Improved Healthcare
Kate Williamson
The symbiotic relationship between medical devices and pharmaceuticals revolutionizes healthcare by enhancing diagnostics, treatment, and disease management. This integration fosters personalized medi...
-
2
How AI Is Addressing Drug Development Challenges in Rare Diseases?
Kate Williamson
Drug development for rare diseases that affect less than 0.1% of the population proves challenging because of restricted data availability and small patient numbers and high project expenses. Modern d...
-
3
What Are the Benefits of Implementing a Modern MES in Pharma?
Kate Williamson
The modern MES will give the pharmaceutical manufacturing companies real-time visibility, automated compliance, and a smoothly integrated production control process. Pharma MES solutions promote effic...
-
4
Reshaping Biologics Production Integrating Human Intelligence, AI, and Digital Twins for a Resilient Biologics Future
Manish Garg
This article examines how biologics manufacturers can unlock a $176 billion biosimilars opportunity by integrating human expertise with AI, digital twins, and robotics. Framed through Industry 5.0, it...
-
5
The Permanent Prescription: Why Gene Therapy Is Rewriting the Rules of Drug Safety
John Praveen
Gene therapy is transforming medicine by offering the potential for one-time, curative treatments for previously untreatable genetic diseases. However, the very characteristic that makes these therapi...
press releases Read more...
Biocodex Invests €15 Million in a New Industrial Platform for Live Biotherapeutic Products
Biocodex an independent French pharmaceutical company announces a million investment to develop an industrial platform in Beauvais France dedicated to Live Biotherapeutic Products LBPs derived from the microbiome Building on more than years of expertise in living microorganisms microbiota fermenta...
Boehringer Ingelheim and SBP Group enter partnership to advance next-generation cancer therapies
Boehringer Ingelheim headquartered in Germany and Sino Biopharmaceutical Limited HK together with its subsidiaries SBP Group today announced a strategic multiprogram option and license agreement to advance potential nextgeneration cancer treatments based on antibodydrug conjugate ADC and Tcell engag...
Nxera Pharma Enters into Global License Agreement with AbbVie for NXE0033744, a Novel EP4 Receptor Agonist for Inflammatory Bowel Disease
Nxera Pharma Co Ltd announces that its subsidiary Nxera Pharma UK Ltd has entered into an exclusive global license agreement the Agreement with AbbVie Inc AbbVie for Nxeras EP agonist program including NXE a novel small molecule EP receptor agonist discovered
Oryzon announces authorization in Spain of VIVALDI, a collaborative clinical study with CETLAM to evaluate iadademstat in combination with standard-of-care therapy in high-risk newly-diagnosed AML subpopulations
Oryzon Genomics SA a clinicalstage biopharmaceutical company and global leader in epigenetics today announced that VIVALDI a Phase Ib pilot study sponsored by CETLAM Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplsicas has been authorized in Spain
Events Read more...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
10 - 11
Nov 2026Extractables & Leachables Europe
Parkhotel Schӧnbrunn, Vienna,...
10 - 10
Nov 2026Women in AI
Real Chemistry, 2nd Floor, Lon...
11 - 13
Nov 2026Frontiers in Cancer Science 2026
One Farrer Hotel,1 Farrer Park...
11 - 12
Nov 2026Medical Device Project and Portfolio Management
Chicago, IL, USA
16 - 17
Nov 2026Analytics for Smarter Decisions in Pharma
London, UK
24 - 25
Nov 2026BioPharma Deals - The Survival Series
Munich, Germany
24 - 27
Nov 2026Pharmtech & Ingredients 2026
Crocus Expo, Pavilion 2, Mosco...
LATEST NEWS Read more...
Portal Innovations and Altitude Lab Partner to Strengthen Utah’s Life Sciences Startup Ecosystem
Portal Innovations a venture development platform supporting earlystage life sciences companies today announced a strategic partnership with Altitude Lab to strengthen the resources available to life sciences entrepreneurs in Salt Lake City Through the partnership Altitude Lab will relocate its acce...
MRM Health and Biocodex establish strategic partnership to strengthen future commercial supply capabilities for CORAL®-based medicines
MRM Health a clinicalstage biotech developing microbiomebased therapies for immunemediated diseases and Biocodex an independent French pharmaceutical company with more than years of experience in the microbiome field today announced the launch of a strategic partnership to establish specialized man...
Breakthrough Therapy Designation granted by the FDA for daridorexant in pediatric insomnia disorder
Idorsia Ltd announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy Designation to daridorexant for the treatment of insomnia disorder in patients to
Evestia Clinical Acquires Emtex Life Science to Further Enhance its Global Full-Service Clinical Research Capabilities
Evestia Clinical a leading independent global specialist Contract Research Organization CRO today announced the acquisition of Emtex Life Science Emtex a specialist regulatory medical writing company headquartered in Belgium The acquisition strengthens Evestia
UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
UroGen Pharma Ltd a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers today announced that the first patient was dosed with UGN a nextgeneration investigational oncolytic virus The Phase trial will evaluate the safety tolera...
Graviton BioScience and CinRx Pharma Form CinRock Pharma to Advance ROCK2-Targeted Therapies for Cardiovascular Disease
Graviton BioScience Corporation Graviton and CinRx Pharma CinRx today announced the formation of CinRock Pharma CinRock a jointly governed biopharmaceutical company established to accelerate the development of novel ROCKtargeted therapies for patients with cardiovascular diseases
